Infinity Pharma (INFI) Misses Q1 EPS by 23c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/30/2026

1. INTC
2. AMZN
3. RDDT
4. PINS
5. COIN
6. FSLR
7. SYK
8. GILD
9. SBUX
10. SNDK

Go back to Infinity Pharma (INFI) Misses Q1 EPS by 23c

Infinity Reports First Quarter 2015 Financial Results and Recent Corporate Developments

May 6, 2015 8:02 AM EDT

- Patient Enrollment in DYNAMOTM Now Expected to Be Completed in Second Half 2015

- DUOTM Enrollment On-Track for Completion in Second Half 2015

- Further Expansion of Duvelisib Development Program Expected in 2015

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced its first quarter 2015 financial results and ongoing progress with duvelisib (IPI-145), an oral, dual inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma. Infinity also provided updated guidance on the enrollment timing for DYNAMO, a Phase... More